https://www.selleckchem.com/pr....oducts/apr-246-prima
00 (95% CI 0.99, 1.0], use of metformin [aHR 1.00 (95% CI 0.82, 1.22)], dipeptidyl peptidase-4 inhibitors [DPP4is; aHR 0.94 (95% CI 0.71, 1.24)] and the development of RA. However, statins demonstrated a protective effect for progression of RA in those with T2DM [aHR 0.76 (95% CI 0.66, 0.88)], with evidence of a duration-response relationship. There is a reduced risk of RA in patients with T2DM that may be attributable to the use of statins. There is a reduced risk of RA in patients with T2DM that may be attributable to the
Like
Comment
Share
